Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To assess the differences in progression-free survival at 6 months in subjects with KRAS wild-type metastatic colorectal cancer receiving second line treatment (after failure of a previous irinotecan and 5FU based regimen) with panitumumab plus XELOX compared to the treatment with XELOX alone, without major safety problems
Inclusion criteria
- metastatic colorectal cancer (mCRC)